Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
Hematol Oncol
; 42(3): e3270, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38590272
ABSTRACT
Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and how many organs are affected. Targeted plasma cell therapy has significantly advanced the clinical management of amyloidosis, with ongoing progress. However, current clinical studies are investigating innovative targets, drug combinations and treatment strategies to improve therapeutic outcomes by minimizing adverse effects and refining patient prognosis in these challenging hematological conditions. In this paper, we review the state of the art regarding the use of anti-amyloid antibodies, as a revolutionary and innovative approach in the current scenario of amyloid treatment.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Amiloidose de Cadeia Leve de Imunoglobulina
/
Amiloidose
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália